NCT04079803View on ClinicalTrials.gov

PTI-125 for Mild-to-moderate Alzheimer's Disease Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

September 9, 2019

Primary Completion Date

March 31, 2020

Study Completion Date

March 31, 2020

Conditions
Alzheimer Disease
Interventions
DRUG

Placebo oral tablet

Oral placebo tablet

DRUG

Simufilam 100 mg tablet

Simufilam 100 mg oral tablet

DRUG

Simufilam 50 mg oral tablet

Simufilam 50 mg oral tablet

Trial Locations (9)

33125

Optimus U, Miami

33157

IMIC, Inc., Palmetto Bay

68005

Cognitive Clinical Trials, Bellevue

68116

Cognitive Clinical Trials, Omaha

77058

Centex Studies, Inc., Houston

78504

Centex Studies, Inc., McAllen

85296

Cognitive Clinical Trials, Gilbert

85374

Cognitive Clinical Trials, Surprise

08755

Advanced Memory Research Institute, Toms River

Sponsors
All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

Cassava Sciences, Inc.

INDUSTRY

NCT04079803 - PTI-125 for Mild-to-moderate Alzheimer's Disease Patients | Biotech Hunter | Biotech Hunter